Gland Pharma and Neuland Laboratories Limited announced a long-term strategic Contract Development and Manufacturing Organization (CDMO) partnership on August 5, 2026, aimed at expanding sterile Active Pharmaceutical Ingredient (API) manufacturing capabilities. The collaboration addresses rising global demand for sterile APIs used in microparticle depot products by combining Neuland's expertise in complex chemistry with Gland Pharma's established sterile manufacturing infrastructure. This partnership strengthens supply resilience for both innovator and generic pharmaceutical companies seeking reliable sources for complex injectable therapies.

The agreement requires Gland Pharma to establish an additional dedicated sterile manufacturing suite at its JNPC facility in Visakhapatnam. The new facility will be constructed and operated in compliance with current Good Manufacturing Practice (cGMP), USFDA, and EU standards. Designed to support Neuland's growing demand, the suite will provide an integrated solution encompassing development, scale-up, regulatory support, and commercial manufacturing.

Partnership Details

The collaboration leverages the complementary strengths of both entities. Neuland contributes its deep expertise in complex API development, process development, and custom manufacturing, supported by a strong track record of serving global clients. Gland Pharma provides its global sterile manufacturing expertise and proven aseptic manufacturing capabilities. Together, they aim to offer a robust and scalable CDMO solution backed by world-class quality and compliance.

Executive Commentary

Srinivas Sadu, Executive Chairman of Gland Pharma Limited, stated that the investment expands the company's capabilities in sterile API manufacturing and supports increasing customer demand. He emphasized that leveraging the complementary strengths of both organizations allows them to provide a scalable solution backed by manufacturing excellence, creating a foundation for sustainable growth.

Saharsh Davuluri, CEO and Managing Director of Neuland Laboratories Limited, noted that demand for sterile APIs continues to grow as pharmaceutical companies advance increasingly complex injectable therapies. He highlighted that the partnership creates a differentiated platform for global customers, strengthening their ability to deliver the quality, reliability, and supply assurance expected from CDMO partners.

Capacity and Strategic Focus

The addition of approximately 1400 kg of annual capacity represents a targeted expansion rather than a broad infrastructure overhaul. By focusing specifically on microparticle depot products and complex sterile APIs, the partnership signals a strategic shift toward high-value, technically difficult formulations. This specialized capacity addition positions both companies to capture market share in segments where supply resilience and regulatory compliance are critical differentiators, rather than competing on volume alone in standard sterile injectables.

Gland Pharma Limited has convened its 48th Annual General Meeting (AGM) for Tuesday, August 25, 2026, at 11:00 A.M. IST, to be held through Video Conferencing (VC) / Other Audio-Visual Means (OAVM) in compliance with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and applicable Ministry of Corporate Affairs (MCA) circulars. The deemed venue for the meeting is the company's Corporate Office at Plot No. 11 & 84, TSIIC, Phase-IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad. The AGM Notice along with the Annual Report for FY 2025-26 has been dispatched electronically to members who have registered their email addresses.

Key AGM Details

The following table summarises the important dates and parameters for the 48th AGM:

Agenda: Dividend and Director Reappointments

The ordinary business at the AGM includes adoption of audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026, along with the Board's Report and Auditor's Report. The Board of Directors has recommended a final dividend of ₹20 per equity share (face value ₹1 each), representing 2000%, for FY 2025-26, subject to shareholder approval. The record date for determining dividend eligibility is August 11, 2026, and payment will be made within 30 days of shareholder approval.

The AGM will also consider the reappointment of two Non-Executive and Non-Independent Directors retiring by rotation:

Both directors draw no remuneration from the Company in their capacity as Non-Executive Directors.

FY 2025-26 Financial Performance Highlights

The Annual Report accompanying the AGM Notice reflects strong operational and financial performance for FY 2025-26. The following table presents key consolidated financial metrics:

Revenue from operations grew 14.5% year-on-year, driven by volume expansion, new contract wins, and higher contribution from differentiated products, particularly in the U.S. market. EBITDA grew by 28% and the Interest Coverage Ratio improved by 62% to 133.85 times. The base business (excluding Cenexi) recorded revenues of ₹45,613 Mn with an EBITDA margin of 36%.

Regulatory Pipeline and Strategic Highlights

During FY 2025-26, Gland Pharma filed 24 ANDAs and received 28 approvals, taking cumulative U.S. ANDA filings to 388 (337 approved, 51 pending). The company launched 31 molecules in the U.S. and rolled out 36 molecules across regulated markets. The GLP-1 platform saw the partnered Liraglutide product expanded to the UK and Australia, with cartridge and pen capacity scaled from ~40 million to 140 million units per year. The company also advanced 15 products into co-development and filed 21 RTU infusion bag products, of which 18 have received approvals.

Shareholder and Document Access

In accordance with SEBI (LODR) (Third Amendment) Regulations, 2024, the AGM Notice and Annual Report for FY 2025-26 are being sent only through electronic mode. Members who have not registered their email IDs will receive a letter with a weblink and QR code to access the documents online. Physical shareholders must submit KYC details to the Registrar and Transfer Agent, MUFG Intime India Private Limited, C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai – 400 083. Demat shareholders should update their KYC with their respective Depository Participants. AGM documents are also available on the company's website ( www.glandpharma.com ), BSE ( www.bseindia.com ), NSE ( www.nseindia.com ), and NSDL ( www.evoting.nsdl.com ).

For TDS-related submissions, members are required to upload requisite forms on or before August 16, 2026. The Scrutinizer for the e-voting process is Ms. D Soumya, Associate Partner, RVR & Associates (Membership No. F11754; CP No. 13199). Voting results will be declared after the AGM and published on the company's website and the NSDL platform.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE068V01023/194b8488-f37c-4e0a-a510-1dccacff9d72.pdf